The 2.3% medical device excise tax could lead to job cuts in the medtech industry by lowering the demand for costly devices and driving U.S. firms to move their operations overseas, writes BioOhio President and CEO Tony Dennis, citing an AdvaMed study. The tax, set to begin in 2013, "is counter to principles of economic growth and job creation" and "may stifle the kind of innovation that is essential to patients and the overall health care system," Dennis notes.

Related Summaries